The Synthesis and Evaluation of Novel ALK Inhibitors Containing the Sulfoxide Structure

Han Yao,Yuanyuan Ren,Feng Wu,Jiadai Liu,Longcai Cao,Ming Yan,Xingshu Li

DOI: https://doi.org/10.1039/d4ra01556h

IF: 4.036

2024-01-01

RSC Advances

Abstract:With ceritinib as the lead, a series of novel compounds containing the sulfoxide structure were synthesized and evaluated as anaplastic lymphoma kinase inhibitors.

What problem does this paper attempt to address?

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents

Feng Wu,Han Yao,Wei Li,Niuniu Zhang,Yangyang Fan,Albert S C Chan,Xingshu Li,Baijiao An

DOI: https://doi.org/10.1016/j.bmcl.2021.128253

IF: 2.94

2021-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Anaplastic lymphoma kinase (ALK) targeted therapies have demonstrated remarkable efficacy in ALK-positive lung adenocarcinomas. Here we synthesized and evaluated sixteen new 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibitors. The optimal compound 9e exhibited excellent antiproliferative activity against non-small cell lung cancer NCI-H2228 cells, which is better than that of Brig-atinib and similar to Ceritinib. Mechanism study revealed that the optimal compound 9e decreased the mito-chondrial membrane potential and arrested NCI-H2228 cells in the G0/G1 phase, finally resulting in cellular apoptosis. It is interesting that 9e could effectively inhibit the migration of NCI-H2228 cells and may be a promising leading compound for chemotherapy of metastatic cancer.
Synthesis and biological evaluation of sulfonamide derivatives containing imidazole moiety as ALK5 inhibitors

Shu-Yan Ding,Yu-Xuan Yang,Chuang Liu,Xu-Yin Quan,Zi-Han Zhao,Cheng-Hua Jin

DOI: https://doi.org/10.1007/s11030-024-10973-y

2024-09-02

Molecular Diversity

Abstract:Four series of sulfonamide derivatives ( 13a – b , 14a – d , 15a – b , and 16a – d ) were synthesized and evaluated for their activin receptor-like kinase 5 (ALK5) inhibitory activities. Of these, compounds 13b (IC 50 = 0.130 μM) and 15a (IC 50 = 0.130 μM) showed the highest inhibitory activities against ALK5 kinase, with activities similar to the positive control LY - 2157299 . Notably, we discovered that introduction of sulfonamide group at the 2-position of the central imidazole ring significantly increased ALK5 inhibitory activity. Compounds 13b and 15a did not show toxicity in A549 cells up to the maximum concentration of 50 μM, and effectively inhibited TGF-β1-induced Smad-signaling and cell motility in A549 cells. The results indicate that compounds 13b and 15a are worth of further development as anticancer agents.

chemistry, multidisciplinary, medicinal, applied
Synthesis and Evaluation of Sulfonamide Derivatives Targeting EGFR790M/L858R Mutations and ALK Rearrangement As Anticancer Agents.

Longcai Cao,Han Yao,Linlin Yu,Yuanyuan Ren,Jiadai Liu,Xingshu Li,Xian Jia

DOI: https://doi.org/10.1016/j.bmc.2023.117241

IF: 3.461

2023-01-01

Bioorganic & Medicinal Chemistry

Abstract:Fourteen new compounds bearing sulfonamide groups that target EGFRT790M/L858R mutations and ALK rearrangement were synthesized and evaluated as dual-target tumor inhibitors. The study on the anti-proliferation activity on cancer cells showed that the sulfonamide derivative with pyrimidine nucleus had much better activities compared with those with quinazoline nucleus. Among them, compound 19e exhibited excellent activity against H1975 cancer cell lines (EGFRT790M/L858R high express) and H2228 cells (ALK rearrangement) with the IC50 values of 0.0215 μM and 0.011 μM, respectively. The ALK and EGFR kinase inhibition assays also provided similar results. Genotype selectivity of EGFR on kinase and cell level, cytotoxicity towards human normal cell lines and cell morphology assay implied that 19e had acceptable selectivity and low toxicity. In addition, the inhibitory activity of 19e on H1975 and H2228 cells cloning and its apoptosis-inducing effect on the two cell lines were studied, and its inhibitory effect on the invasion and migration of tumor cells were also investigated. All the results show that 19e is worthy of further study.
Discovery of Potent and Effective Inhibitors Containing Sulfoxide Structures Targeting EML4-ALK Rearrangement and EGFR Mutant Non-Small Cell Lung Cancer

Baijiao An,Yangyang Fan,Wei Li,Wenyan Nie,Haoran Nie,Mengxuan Wang,Jie Feng,Han Yao,Yin Zhang,Xingshu Li,Geng Tian

DOI: https://doi.org/10.1016/j.bioorg.2023.106653

IF: 5.307

2023-01-01

Bioorganic Chemistry

Abstract:For non-small cell lung cancer patients with dual mutations in EGFR and ALK, there are currently no effective therapies. Consequently, novel EGFR/ALK dual-target inhibitors are urgently needed for the treatment of NSCLC. Here, we designed a series of highly effective small molecule dual inhibitors of ALK and EGFR. The biological evaluation highlighted that most of these new compounds could effectively inhibit both ALK and EGFR in enzymatic and cellular assays. Compound (+)-8l was investigated for its antitumor properties, and it was found that (+)-8l blocked the phosphorylation of EGFR and ALK induced by ligands and inhibited phosphorylation-ERK and phosphorylation-AKT induced by ligands. Furthermore, (+)-8l also induces apoptosis and G0/G1 cell cycle arrest in cancer cells and inhibits proliferation, migration, and invasion. Notably, (+)-8l significantly suppressed tumor growth in the H1975 cell-inoculated xenograft model (20 mg/kg/d, TGI: 96.11%), PC9 cell-inoculated xenograft model (20 mg/kg/d, TGI: 96.61%) and EML4 ALK-Baf3 cell-inoculated xenograft model (30 mg/kg/d, TGI: 80.86%). These results highlight the differentiated potential of (+)-8l to inhibit ALK rearrangement and EGFR mutation in NSCLC.
Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors

Pierre-Yves Michellys,Bei Chen,Tao Jiang,Yunho Jin,Wenshuo Lu,Thomas H. Marsilje,Wei Pei,Tetsuo Uno,Xuefeng Zhu,Baogen Wu,Truc Ngoc Nguyen,Badry Bursulaya,Christian Lee,Nanxin Li,Sungjoon Kim,Tove Tuntland,Bo Liu,Frank Sun,Auzon Steffy,Tami Hood

DOI: https://doi.org/10.1016/j.bmcl.2015.11.049

IF: 2.94

2016-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor superfamily. Expression of ALK in normal human tissues is only found in a subset of neural cells, however it is involved in the genesis of several cancers through genetic aberrations involving translocation of the kinase domain with multiple fusion partners (e.g., NPM-ALK in anaplastic large cell lymphoma ALCL or EML4-ALK in non-small cell lung cancer) or activating mutations in the full-length receptor resulting in ligand-independent constitutive activation (e.g., neuroblastoma). Here we are reporting the discovery of novel and selective anaplastic lymphoma kinase inhibitors from specific modifications of the 2,4-diaminopyridine core present in TAE684 and LDK378. Synthesis, structure activity relationships (SAR), absorption, distribution, metabolism, and excretion (ADME) profile, and in vivo efficacy in a mouse xenograft model of anaplastic large cell lymphoma are described.
Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

Hong Chen,Ridong Li,Xianling Ning,Xuyang Zhao,Yan Jin,Yuxin Yin

DOI: https://doi.org/10.1016/j.ejmech.2019.05.060

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for development of various tumor types. In this study, we synthesized a series of novel 2,4-diarylaminopyrimidine derivatives possessing a unique N-(3-pyridinylmethyl)urea moiety as ALK inhibitors. The most promising analog 5m bearing a 3-methoxy-4-morpholinophenyl substituent significantly inhibited proliferation of ALK positive H3122 and Karpas-299 cells with IC50 values about 10 nM, which were comparable with positive control LDK378. Compound 5m suppressed phosphorylation of ALK and its downstream proteins, and showed low cytotoxicity on normal human primary fibroblast cells (BJ cells). The binding mode of 5m was proposed by docking simulation, which explains the important role of N-(3-pyridinylmethyl)urea moiety. Furthermore, compound 5m exhibited favorable liver microsomal stability and significant efficacy in H3122 xenograft mice model. Interestingly, compound 5m also showed broader anti-proliferative activity on other human tumor cell lines, which was different from other ALK inhibitors.
Synthesis and Evaluation of Novel Alkannin and Shikonin Oxime Derivatives As Potent Antitumor Agents.

Rubing Wang,Xu Zhang,Hualong Song,Shanshan Zhou,Shaoshun Li

DOI: https://doi.org/10.1016/j.bmcl.2014.07.012

IF: 2.94

2014-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A set of forty alkannin and shikonin oxime derivatives were firstly designed and synthesized. Their cytotoxicities against three kinds of tumor cells and a normal cell line were tested and compared with alkannin and shikonin. The cell-based investigation demonstrated that some oxime derivatives were more or comparatively effective to the lead compounds, especially their selective and excellent antitumor activities towards K562 cells with no toxicity in normal cells. We may conclude that oximate modification to the mother nucleus of alkannin and shikonin is an available approach to acquire potent antitumor agents.
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Thomas H Marsilje,Wei Pei,Bei Chen,Wenshuo Lu,Tetsuo Uno,Yunho Jin,Tao Jiang,Sungjoon Kim,Nanxin Li,Markus Warmuth,Yelena Sarkisova,Frank Sun,Auzon Steffy,AnneMarie C Pferdekamper,Allen G Li,Sean B Joseph,Young Kim,Bo Liu,Tove Tuntland,Xiaoming Cui,Nathanael S Gray,Ruo Steensma,Yongqin Wan,Jiqing Jiang,Greg Chopiuk,Jie Li,W Perry Gordon,Wendy Richmond,Kevin Johnson,Jonathan Chang,Todd Groessl,You-Qun He,Andrew Phimister,Alex Aycinena,Christian C Lee,Badry Bursulaya,Donald S Karanewsky,H Martin Seidel,Jennifer L Harris,Pierre-Yves Michellys

DOI: https://doi.org/10.1021/jm400402q

IF: 8.039

2013-01-01

Journal of Medicinal Chemistry

Abstract:The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.
Design, Synthesis and Biological Evaluation of Novel Antitumor Spirodihydrothiopyran-Oxindole Derivatives

Wei Liu,Shuqiang Chen,Fan Zhang,Shipeng He,Shengzheng Wang,Chunquan Sheng

DOI: https://doi.org/10.1016/j.bmcl.2019.04.037

IF: 2.94

2019-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Sulfur containing spiroheterocyclic oxindoles are promising privileged scaffolds in medicinal chemistry and drug discovery. Previously, we identified a new class of spirodihydrothiopyran-oxindoles with good in vitro antitumor activity against A549 lung cancer cell line. Herein, various spirooxindole-dihydrothiopyrans with diverse substitutions were synthesized and assayed to investigate the structure-activity relationships. Among the derivatives, compounds 4b, 4i, 4m, 4n and 4q displayed superior or comparable antitumor activity than nutlin-3. Molecular mechanism study revealed this scaffold displayed moderate MDM2 inhibitory activity, significantly induced cancer cell apoptosis and arrested cell cycle at G0/G1 phase, which represented a good lead compound for antitumor drug discovery.
Synthesis And Biological Evaluation Of Novel Acenaphthene Derivatives As Potential Antitumor Agents

Yong-Mei Xie,Yi Deng,Xiao-Yun Dai,Jie Liu,Liang Ouyang,Yu-Quan Wei,Ying-Lan Zhao

DOI: https://doi.org/10.3390/molecules16032519

IF: 4.6

2011-01-01

Molecules

Abstract:Twelve novel acenaphthene derivatives have been synthesized. The structures of all compounds were confirmed by (1)H-NMR, MS and elemental analysis. Their antitumor activities were evaluated in six human solid tumor cell lines, namely non-small cell lung cancer (H460), human colon adenocarcinoma (SW480), human breast cancer cell (MDA-MB-468 and SKRB-3), human melanoma cell (A375) and human pancreatic cancer (BxPC-3). Among them, compound 3c shows the best antitumor activity against SKRB-3 cell line, as high as the positive control adriamycin.
Novel anaplastic lymphoma kinase inhibitors targeting clinically acquired resistance.

Xiaoyun Lu,Ke Ding

DOI: https://doi.org/10.1021/jm500178r

IF: 8.039

2014-01-01

Journal of Medicinal Chemistry

Abstract:The study by Huang et al. is an excellent example of rational structure-based and lipophilic-efficiency optimization of crizotinib (Xalkori) aimed at novel ALK inhibitors capable of overcoming clinically acquired resistance against the current drug in NSCLC patients. One of the most promising new compounds, 8e, displayed subnanomolar potency against ALK(WT) and a panel of the crizotinib-resistant mutants and demonstrated robust in vivo antitumor efficacy. The super suppressing potency of this compound on ROS1 kinase may also indicate its great potential to overcome the resistance associated with the most recently identified ROS1 mutation.
Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1

Yu Wang,Guogang Zhang,Gang Hu,Yanxin Bu,Hongrui Lei,Daiying Zuo,Mengting Han,Xin Zhai,Ping Gong

DOI: https://doi.org/10.1016/j.ejmech.2016.06.056

2016-11-10

Abstract:A series of 4-arylaminopyrimidine derivatives possessing a hydrazone moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against ALK-addicted KARPAS299 and ROS1-addicted HCC78, while also showing much less potent activity against A549, H460 and HT-29, whose growth were not dependent on ALK and/or ROS1, as compared with crizotinib and ceritinib. The most promising compound, 7b, showed high antiproliferative effects on ALK-addicted KARPAS299 and ROS1-addicted HCC78 cell lines with IC50 of 20 nM and 28 nM, respectively, but showed no inhibitory activity against A549, H460 and HT-29. The enzymatic assay identified 7b as a potent and selective ALK and ROS1 dual inhibitor with IC50 of 2.5 nM and 2.7 nM, respectively. It also exhibited good inhibitory activity against the L1196M ALK with an IC50 value of 67 nM.
Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

Fang Qiao,Yong Yin,Yu-Ning Shen,She-Feng Wang,Shao Sha,Xun Wu,Ai-Min Lu,Chen Xu,Wei-Ming Zhang,Hai-Liang Zhu

DOI: https://doi.org/10.1039/c4ra11780h

IF: 4.036

2015-01-01

RSC Advances

Abstract:A series of 4-alkoxyquinazoline derivatives containing the 1,3,4-oxadiazole scaffold were designed and synthesized. Their inhibitory activities were tested against A549, MCF-7 and Hela. 4j showed the most potent inhibitory activity and may be a potential anticancer agent.
Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy

Jing Ren,Yong Gao,Wei Shi,Sheng Xu,Qinglin Wang,Damin Zhao,Lingming Kong,Wei Song,Xiaojin Wang,Ying Zhang,Xiangyi He,Yan Wang,Shunyu Tong,Peng Lu,Yang Li,Hongjiang Xu,Yinsheng Zhang

DOI: https://doi.org/10.1016/j.bmc.2022.117071

2022-10-27

Abstract:ALK is an attractive therapeutic target for the treatment of non-small cell lung cancer. As an emerging element in medicinal chemistry, boron has achieved great success in the discovery of antitumor drugs and antibacterial agents. Through construction of a BCC (boron-containing compound) compound library and broad kinase screening, we found the ALK inhibitor hit compound 10a . Structural optimization by CADD and isosterism revealed that lead compound 10k has improved activity (ALK L1196M IC 50 = 8.4 nM, NCI-H2228 cells IC 50 = 520 nM) and better in vitro metabolic stability (human liver microsomes, T 1/2 = 238 minutes). Compound 10k showed good in vivo efficacy in a nude mouse NCI-H2228 lung cancer xenograft model with a TGI of 52%. Molecular simulation analysis results show that the hydroxyl group on the oxaborole forms a key hydrogen bond with Asn1254 or Asp1270, and this binding site provides a new idea for drug design. This is the first publicly reported lead compound for a boron-containing ALK inhibitor.

biochemistry & molecular biology,chemistry, medicinal, organic
Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents

jie chen,jun yan,jinhui hu,yanqing pang,ling huang,xingshu li

DOI: https://doi.org/10.1039/c5ra14888j

IF: 4.036

2015-01-01

RSC Advances

Abstract:A series of novel chalcone analogues were designed, synthesized and evaluated as anticancer agents. The results of antiproliferative activity tests showed that most of the analogues exhibited moderate to very good antiproliferative activities with GI(50) values in the micromol to sub-micromol range. Especially compound 10a gave 0.026 mu M to 0.035 mu M GI(50) for five cancer cell lines. The mechanistic studies including tubulin polymerization inhibition, disruption of microtubule dynamics and cell cycle arrest assay demonstrated that compound 10a could effectively inhibit in vitro cellular tubulin polymerization, interfere with the mitosis, resulting in a prolonged G2/M cell cycle arrest and ultimately lead to cell apoptosis of cancer cells. Taken together, these results suggested that 10a may became a promising lead compound for development of new anticancer drugs.
Synthesis and biological evaluation of the novel antitumor agent 3'-monosubstituted chalcone derivatives

luyao wang,hongye zhao,dan wu,long qin,yuou teng,kui lu

DOI: https://doi.org/10.2991/ic3me-15.2015.101

2015-01-01

Abstract:Seven novel 3'-mono-substituted chalcone derivatives were synthesized from 2,4-dihydroxyacetophenone in 4 steps in 18-31% overall yield. Their structures were confirmed by H-1 NMR. The anticancer activity of these new target compounds (4 similar to 10) against human leukemia K562 cells were evaluated by MTT assay in vitro. This study leads to the identification of one highly active molecule, compounds 10 (IC50 = 5.60 mu M) against K562.
Synthesis and Evaluation of Novel Isoxazolyl Chalcones As Potential Anticancer Agents.

Maosheng Wan,Linyan Xu,Li Hua,Ailing Li,Shuqing Li,Wenjing Lu,Yue Pang,Chengbo Cao,Xiangguo Liu,Peifu Jiao

DOI: https://doi.org/10.1016/j.bioorg.2014.03.004

IF: 5.307

2014-01-01

Bioorganic Chemistry

Abstract:A series of novel isoxazolyl chalcones were synthesized and evaluated for their activities in vitro against four types of human non-small cell lung cancer cells, including H1792, H157, A549 and Calu-1 cells. The preliminary biological screening showed that compounds 5d and 5f-i exhibited significant cytotoxicity, particularly, compounds 5f and 5h were identified as the most potent anticancer agents with IC50 values 1.35-2.07 mu M and 7.27-11.07 mu M against H175, A549 and Calu-1 cell lines, respectively. Compounds 5f-i could induce apoptosis in A549 cells by death receptor 5 (DR5) mediated extrinsic pathways. The preliminary structure-activity relationship study showed that compounds bearing electron withdrawing groups (EWG) at the 2-position of the phenyl ring in Ar group were more effective than those with EWG at 4-position. These results further demonstrated that the scaffolds designed in this work might lead to the discovery of novel anti-lung cancer agents. (C) 2014 Elsevier Inc. All rights reserved.
Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

Chunjiang Wu,Min Wang,Qidong Tang,Rong Luo,Le Chen,Pengwu Zheng,Wufu Zhu

DOI: https://doi.org/10.3390/molecules201019361

2015-01-01

Abstract:Two series of novel sorafenib analogs containing a sulfonylurea unit were synthesized and their chemical structures were confirmed by 1H-NMR, 13C-NMR, MS spectrum and elemental analysis. The synthesized compounds were evaluated for the cytotoxicity against A549, Hela, MCF-7, and PC-3 cancer cell lines. Some of the compounds showed moderate cytotoxic activity, especially compounds 1-(2,4-difluorophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (6c) and 1-(4-bromophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (6f) with the IC50 values against four cancer cell lines ranging from 16.54 ± 1.22 to 63.92 ± 1.81 μM, respectively. Inhibitory rates against vascular endothelial growth factor receptor-2 (VEGFR2/KDR) kinase at 10 μM of target compounds were further carried out in this paper in order to investigate the target of these compounds. Structure-activity relationships (SARs) and docking studies indicated that the sulfonylurea unit was important to these kinds of compounds. None of the substitutions in the phenoxy group and small halogen atoms such as 2,4-difluoro substitution of the aryl group contributed to the activity. The results suggested that sulfonylurea sorafenib analogs are worthy of further study.
Synthesis and Biological Evaluation of Novel Fluorinated Anticancer Agents Incorporating the Indolin-2-One Moiety

Shuai-Yu Wang,Li-Jun Wang,Bo Jiang,Ning Wu,Xiang-Qian Li,Jiao Luo,Bao-Cheng Wang,Ren-Shuai Zhang,Qi Xu,Da-Yong Shi

DOI: https://doi.org/10.1039/c5ra19617e

IF: 4.036

2015-01-01

RSC Advances

Abstract:A series of novel fluorinated anticancer agents containing the indolin-2-one moiety were designed, synthesized and evaluated for their anticancer activities in vitro.
Synthesis and Biological Evaluation of a Novel Class of Coumarin Derivatives.

Hong Li,Xiaomin Wang,Guichao Xu,Li Zeng,Kai Cheng,Pengchao Gao,Qing Sun,Wei Liao,Jianwei Zhang

DOI: https://doi.org/10.1016/j.bmcl.2014.09.051

IF: 2.94

2014-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:In this study, several novel coumarin derivatives, 7-hydroxy-2-oxo-2H-chromene-3-carboxyl-Trp-Trp-AA-OBzl compounds, were designed and synthesized as potential anticancer agents. Their in vitro cytotoxic activities were evaluated using methylthiazoltetrazolium (MTT) assay. The anti-tumor activity of the newly coumarin derivatives was determined in a S180 bearing mouse model and some of the compounds demonstrated tumor growth inhibition similar to the positive control, doxorubicin. Compared to doxorubicin, most of the compounds exhibited enhanced immunologic function suggesting a relatively minor toxic effect. The intercalation of the coumarin derivatives synthesized with calf thymus (CT) DNA was also studied.

The Synthesis and Evaluation of Novel ALK Inhibitors Containing the Sulfoxide Structure

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents

Synthesis and biological evaluation of sulfonamide derivatives containing imidazole moiety as ALK5 inhibitors

Synthesis and Evaluation of Sulfonamide Derivatives Targeting EGFR790M/L858R Mutations and ALK Rearrangement As Anticancer Agents.

Discovery of Potent and Effective Inhibitors Containing Sulfoxide Structures Targeting EML4-ALK Rearrangement and EGFR Mutant Non-Small Cell Lung Cancer

Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors

Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

Synthesis and Evaluation of Novel Alkannin and Shikonin Oxime Derivatives As Potent Antitumor Agents.

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirodihydrothiopyran-Oxindole Derivatives

Synthesis And Biological Evaluation Of Novel Acenaphthene Derivatives As Potential Antitumor Agents

Novel anaplastic lymphoma kinase inhibitors targeting clinically acquired resistance.

Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy

Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents

Synthesis and biological evaluation of the novel antitumor agent 3'-monosubstituted chalcone derivatives

Synthesis and Evaluation of Novel Isoxazolyl Chalcones As Potential Anticancer Agents.

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

Synthesis and Biological Evaluation of Novel Fluorinated Anticancer Agents Incorporating the Indolin-2-One Moiety

Synthesis and Biological Evaluation of a Novel Class of Coumarin Derivatives.